PT - JOURNAL ARTICLE AU - Mavian, Carla N. AU - Tagliamonte, Massimiliano S. AU - Alam, Meer T. AU - Sakib, S. Nazmus AU - Cash, Melanie N. AU - Riva, Alberto AU - De Rochars, V. Madsen Beau AU - Rouzier, Vanessa AU - Pape, Jean William AU - Morris, J. Glenn AU - Salemi, Marco AU - Ali, Afsar TI - Re-emergence of cholera in Haiti linked to environmental <em>V. cholerae</em> O1 Ogawa strains AID - 10.1101/2022.11.21.22282526 DP - 2022 Jan 01 TA - medRxiv PG - 2022.11.21.22282526 4099 - http://medrxiv.org/content/early/2022/11/27/2022.11.21.22282526.short 4100 - http://medrxiv.org/content/early/2022/11/27/2022.11.21.22282526.full AB - BACKGROUND On September 25th, 2022, cholera re-emerged in Haiti.OBJECTIVES/METHODS Toxigenic Vibrio cholerae O1 Ogawa were isolated on October 3rd &amp; 4th, 2022, from cholera case patients in Port-au-Prince. The two new genomes were compared with genomes from 2,129 V. cholerae O1 isolated worldwide, including 292 Haitian strains from 2010-2018.RESULTS Phylogenies conclusively show the 2022 strains clustering within the Haitian monophyletic clade dating back to the 2010 outbreak. Strains shared a most recent common ancestor with a 2018 Haitian Ogawa strain isolated from the aquatic ecosystem, and cluster with the Ogawa clade that was circulating in 2015-2016.CONCLUSIONS Re-emergence of cholera in Haiti is the likely result of a spill-over event at the aquatic-human interface related to persistence of V. cholerae O1 in the environment.One-Sentence Summary We analyzed the full genome of two V. cholerae strains isolated from Haitian patients infected during the early days of the current 2022 epidemic, with data indicating that they originated from strains that have been circulating undetected at sub-epidemic levels in the aquatic environment.Competing Interest StatementThe authors have declared no competing interest.Funding StatementFunding for these studies was provided in part by grants from the National Institute of Allergy and Infectious Diseases (R01AI128750; R01AI123657; R01AI097405) award to JGMJ.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:University of Florida Institutional Review Board gave ethical approval for this workI confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe genomic sequences have been deposited with NCBI under Sequence Read Archive (SRA) under BioProject ID: PRJNA900623. All other data are available in the Supplementary Information. Xml, global maximal likelihood and MCC trees are available at https://github.com/cmavian/CholeraHaiti2022.